Frequently Asked Questions

A1: Many traditional premium fillers are biphasic or monophasic polydensified. By contrast, the ZartauxFill+GF portfolio is engineered with a proprietary monophasic, monodensified hyaluronic acid matrix using the Swiss-patented S.C.E.D.I.S. technology. This molecular framework allows the gel to distribute evenly and integrate smoothly within the surrounding tissue, supporting natural, dynamic facial movement while minimizing the risk of the Tyndall effect and product migration.

A2: The ZartauxFill+GF collection is formulated across a calibrated rheological range. It delivers viscoelastic G′ (storage modulus) values of approximately 200 to 300 Pa, offering strong structural support while preserving soft-tissue elasticity. Each variant is tuned to its indication (for example, Classic for moderate correction and Elite for deeper volumising), with a highly predictable degradation profile. Correction was sustained to 52 weeks in clinical evaluation, with a designed duration of 12 to 18 months depending on the variant, injection depth and individual metabolism.

A3: Yes. Reversibility and safety are engineered into the S.C.E.D.I.S. technology behind every Zartaux formulation. Because S.C.E.D.I.S. creates a monophasic, monodensified hyaluronic acid matrix that preserves the natural properties of HA and degrades predictably, every Zartaux filler is fully bioabsorbable and reversible with hyaluronidase. In the event of an aesthetic adjustment or a clinical emergency, the monophasic matrix responds predictably and can be safely dissolved using standard units of hyaluronidase, administered by a trained practitioner.

A4: Sandine Zartaux operations adhere to international biomedical manufacturing standards. The ZartauxFill+GF injectable line is an EU Class III medical device carrying CE marking (EU MDR 2017/745, CE 0653) and is engineered with the Swiss-patented S.C.E.D.I.S. technology. It is manufactured under certified ISO 9001, ISO 13485 (medical devices) and GMP (ISO 22716) quality systems. Every device undergoes full biocompatibility evaluation in line with the EN ISO 10993 series and terminal sterilisation to validated standards, is supplied with a patient implant card under Article 18 of the EU MDR, and is continuously monitored through post-market surveillance under MDR Articles 83 to 86.

A5: ZartauxFill+GF is a medical dermal filler for the restoration of facial volume and soft-tissue architecture in age-related or pathological volume loss, injected from the mid-dermis to the subcutaneous layer. Depending on the variant, its indications include nasolabial folds, marionette lines and perioral lines; restoration of cheek, midface and temple volume; correction of the tear-trough and infraorbital hollow; facial contour deformities due to tissue loss from accident or disease; and facial lipoatrophy, including HIV-associated facial lipoatrophy. It also supports dermal hydration and extracellular matrix integrity in dermal volume depletion. Each treatment is performed by a qualified physician. Please refer to the Instructions for Use for the full intended purpose, indications and contraindications.

A6: S.C.E.D.I.S. (Stable Cross-linked Enhanced Dermal Integration System) is the Swiss-patented cross-linking technology behind ZartauxFill+GF. It uses divinyl sulfone (DVS) to form stable bonds while preserving the natural properties of hyaluronic acid, producing a monophasic, monodensified gel of ultrafine HA neo-spheres (the SCEDIS-MSCS method). This structure allows the gel to integrate evenly within the tissue and support natural facial movement, while minimizing the risk of migration and the Tyndall effect and degrading predictably for full bioabsorption.

A7: Many established HA fillers are biphasic or monophasic polydensified. ZartauxFill+GF is monophasic and monodensified, engineered with the Swiss-patented S.C.E.D.I.S. technology to integrate evenly within the surrounding tissue. In clinical evaluation it delivered correction and durability comparable to an established monophasic polydensified HA filler, while patients rated it higher for naturalness of feel. It is fully bioabsorbable and reversible with hyaluronidase. As with any filler, results depend on the variant, the injection technique and the treating physician.

A8: As with all hyaluronic acid dermal fillers, the most common side effects are mild, transient injection-site reactions such as redness, swelling, bruising and tenderness, which usually resolve within a few days. Less frequently, temporary lumps or discolouration may occur. Rare but serious risks relate to injection technique, including vascular events such as vascular occlusion; for this reason treatment must be performed by a trained physician with hyaluronidase available. Please refer to the Instructions for Use for the complete list of warnings and adverse events.

A9: As with all hyaluronic acid dermal fillers, ZartauxFill+GF should not be used in patients with known hypersensitivity to hyaluronic acid or any component of the device, in areas with active infection or inflammation, or in patients with autoimmune connective-tissue disease or receiving immunosuppressive therapy. It is not recommended during pregnancy or breastfeeding. A qualified physician will assess suitability during consultation. Please refer to the Instructions for Use for the full list of contraindications and warnings.